ERAS: Trend Dislocation Reversion detected on 11 Nov 2026

All prices, scores, and news on this page reflect data available before market open on .

Free example: 1 of 51 setups from the 11 Nov 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

On 11 Nov 2026, our scan flagged ERAS as a trend dislocation reversion setup scoring 81 out of 98 (Strong tier), with a 75% win probability based on our historical pattern database and a 0.64 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $15.48, the conservative target is $16.49 with a stop at $13.90.

81 of 98
Strong
75%
High
0.64 : 1
$1.01 to target $1.58 to stop
Swing Trading Plan
Entry
$15.48
$16.49
$13.90
2-7 trading days
Exp. Reward
+$0.64
Exp. Risk
-$0.30

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup
ERAS is forming a trend dislocation reversion pattern, currently trading at $15.48 against key support at $13.11 and resistance at $16.03. The pattern achieved strong technical quality with a structure score of 15.0/15, volume score of 12.0/12, and breakout score of 13.0/13, generating an overall score of 81 and a 75% win probability. Volume is running 1.28x average at 5.98M shares, supporting breakout potential. RSI at 54.61 indicates balanced momentum, and the stock sits 600% above its 52-week low, recovering from severe oversold conditions. The pattern suggests mean reversion is taking hold after a brutal 3-month decline of 16.68%.
Stock Context
Erasca is scheduled to report Q3 2026 earnings after market close on November 11, the exact date of this pattern detection. This timing is critical—analysts expect the company to post a loss of $0.1301 per share. Erasca is a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, with a pipeline targeting key signaling nodes, RAS directly, and escape routes. The company made strategic progress in 2026: Erasca raised $836.2M in equity while posting a $227.5M first-half loss, driven largely by a $150M in-process R&D charge to expand worldwide rights to ERAS-0015, a pan-RAS molecular glue. ERAS-0015 is the lead pipeline candidate. Pre-revenue biotech companies often see volatility around earnings, but the capital raise signals management confidence in pipeline advancement.
What to Expect
A successful breakout would clear resistance at $16.03 with volume confirmation above the 1.28x relative volume threshold. The pattern targets a conservative measured move to $16.49, representing a 6.5% gain from current price. Given the 75.15% win probability and mean reversion structure, historical data suggests pullback failures often reverse quickly. Invalidation occurs decisively below support at $13.11; a breakdown through that level would negate the dislocation reversion setup and signal continuation of the downtrend. The setup indicates the pattern has moderate upside defined risk given the wide support cushion.
Risk Factors
Erasca has a recent history of earnings misses—Q2 reported -$0.14 EPS versus consensus -$0.11, and the company has missed consensus on several recent quarters. Class action lawsuits were filed against the company in August 2026, adding legal overhang. Analysts project full-year losses of $0.49 and $0.65 next year, underscoring a lengthy path to profitability. The stock's 1.36 beta indicates elevated volatility relative to the broader market; the 7.04% ATR suggests daily swings of $1.09, which could easily exceed the pattern's $1.38 target range. While the Health Care sector shows bullish regime (+0.82), the broad market is bearish (-0.54), creating headwinds. Earnings data release after market close today adds tail risk to the pattern within the same session.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is ERAS a good swing trade?
ERAS scored 81 out of 98 on our trend dislocation reversion scan, with a 75% historical win probability over a 2-7 trading days hold. Strong setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $15.48, with a conservative target of $16.49 and a stop loss at $13.90.
What would invalidate this trend dislocation reversion setup?
A close below the stop loss at $13.90 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical trend dislocation reversion setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bearish -0.54
-1.0 0 +1.0
Health Care Sector
Bullish 0.82
-1.0 0 +1.0
Overall Score
40 of 40
Exceptional
Pattern Quality
16 of 20
Strong
Setup
15 of 20
Good
R/R
10 of 18
Fair
Context
Pattern Quality Score
15 of 15
Exceptional
Structure
13 of 13
Exceptional
Breakout
12 of 12
Exceptional
Volume
Recent Performance
+5.7%
1W
+1.7%
2W
+0.1%
1M
-16.7%
3M
Momentum & Trend
RSI (14)
54.6
Neutral
MACD Histogram
+0.12
Bullish
Bollinger Band Position
85.9%
Upper Zone
Volatility & Risk
20-Day Volatility
0.81
Very High
ATR %
7.0%
High
Beta
1.36
Above Mkt
Volume Analysis
Volume Ratio
1.28x
Above Avg
20-Day Avg Vol
4.7M
shares / day
Current Volume
6.0M
shares traded
Price Levels
52W High
$24.28
Target
$16.49
Resistance
$16.03
Current
$15.48
Stop Loss
$13.90
Support
$13.11
52W Low
$2.21
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.